Research programme: recombinant methioninase - AntiCancer

Drug Profile

Research programme: recombinant methioninase - AntiCancer

Alternative Names: AC 9301; AC-9501; Methioninase; ONCase; ONCase-PEG; PEG AC 9501; PEG-methioninase; PEG-rMETase; Recombinant L-methionine gamma-lyase; Recombinant methionine α, γ-lyase; rMETase

Latest Information Update: 24 Jul 2009

Price : $50

At a glance

  • Originator AntiCancer
  • Developer AntiCancer; Shionogi
  • Class Antineoplastics; Carbon sulfur lyases; Polyethylene glycols
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 24 Jul 2009 Preclinical development is ongoing in USA and Japan
  • 12 Sep 2007 AntiCancer is seeking a partner to develop PEGylated methioninase as a treatment for HIV-infected patients with Pneumocystis pneumonia(http://www.anticancer.com)
  • 08 Feb 2007 Preclinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top